Protocol Ledger

NCT07157007 · Phase II · RECRUITING

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

Interventional Phase II clinical trial protocol NCT07157007 sponsored by Traws Pharma in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-16 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07157007
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07157007
Protocol FieldVerified Registry Value
NCT IdentifierNCT07157007
Consolidated Lead SponsorTraws Pharma
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2025-09-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07157007
Hospital Research SiteLocationSite Profile
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
Inha University HospitalIncheon, South KoreaOpen Hospital Dossier ->
Taichung Veterans General HospitalTaichung, TaiwanOpen Hospital Dossier ->
Taipei Medical University HospitalTaipei, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI